olezarsen (Tryngolza)
Jump to navigation
Jump to search
Indications
- treatment of familial chylomicronemia syndrome
- severe hypertriglyceridemia[2]
Dosage
* at 6 months reduction in serum triglycerides 58-63% with 50 mg, 61-72% with 80 mg dose[1][2]
Adverse effects
- injection site reactions (pain, redness, swelling)
- upper respiratory tract infections
- headache
- back pain
- allergic reactions
- hepatitis, pancreatitis
- tolerable short-term safety profile[3]
Mechanism of action
- antisense oligonucleotide targeting apolipoprotein C-III (ApoC-III)
- inhibits production of apolipoprotein C-III (ApoC-III), a protein that slows catabolism of triglycrides
More general terms
References
- ↑ 1.0 1.1 Bergmark BA, Marston NA, Prohaska TA, et al. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. N Engl J Med. 2025 Aug 30 PMID: https://pubmed.ncbi.nlm.nih.gov/40888739 https://www.nejm.org/doi/10.1056/NEJMoa2507227
- ↑ 2.0 2.1 2.2 Marston NA, Bergmark BA, Alexander VJ et al for the Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. CORE-TIMI 72a and CORE2-TIMI 72b Investigators. N Engl J Med. 2025 Nov 8. PMID: https://pubmed.ncbi.nlm.nih.gov/41211918 https://www.nejm.org/doi/10.1056/NEJMoa2512761
- ↑ 3.0 3.1 Emara A, Mansour A, Aboeldahab H, et al. Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026 Apr 7. PMID: https://pubmed.ncbi.nlm.nih.gov/41943994